Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltratio...(Factors that may cause such differences ...),Health

Date:6/6/2008

Factors that may cause such differences include the risks that Nephros may not be able: (i) to obtain funding if and when needed or on favorable terms; (ii) to continue as a going concern; (iii) to liquidate its short-term investments when needed to fund its operations; (iv) to maintain compliance with the AMEX's continued listing standards; (v) to demonstrate in pre-clinical or clinical trials the anticipated efficacy, safety or cost savings of products that appeared promising to Nephros in research or clinical trials; (vi) to obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (vii) to have its technologies and products accepted in current or future target markets; or (viii) to secure or enforce adequate legal protection, including patent protection, for its products. More detailed information about Nephros and the risk factors that may affect the realization of forward-looking statements is set forth in Nephros' filings with the SEC, including Nephros' Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007, and Nephros' Quarterly Report on Form 10-Q for the period ended March 31, 2008. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Nephros does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

'/>"/>

SOURCE Nephros, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
4. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
5. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
6. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
7. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
8. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
9. PacificGMP Completes GMP Product Fill for Trius Therapeutics
10. Cardinal Health Completes Enturia Acquisition
11. DaVita Clinical Research Completes Record Number of Renal Trials in 2007